Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
Commentary|Articles|May 5, 2026
Could Orforglipron Change Obesity Treatment Forever?
Fact checked by: Ron Panarotti
A new oral GLP-1 therapy could reshape obesity treatment by improving access, convenience, and patient uptake compared with injectable options.
Advertisement
Advertisement
In this Q&A with Pharmacy Times, Richard Frank, MD, chief medical officer at Vida, discusses how emerging oral GLP-1 therapies may shift the obesity treatment landscape by offering a more convenient alternative to injectables, potentially improving patient adherence and earlier initiation of care. He highlights key differences in efficacy, tolerability, and real-world use, while emphasizing the importance of individualized treatment selection. Frank also explores how expanded therapeutic options could enhance access and flexibility for patients and providers.
Related to this article
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
Advertisement
Advertisement